

A1
cont

- (c) hybridizing a reference polynucleotide to said overhangs of probe polynucleotides in a second array to generate a reference hybridization pattern; and
- (d) determining the presence of a mutation in the target polynucleotide by comparing the reference and target hybridization patterns.

2. The method of claim 1, wherein in step b), the hybridized target polynucleotide is ligated to the probe.
3. The method of claim 1, wherein in step c), the hybridized reference polynucleotide is ligated to the probe.
4. The method of claim 1, wherein the overhangs have free 5'-ends.
5. The method of claim 1, wherein the overhangs have free 3'-ends.
6. The method of claim 1, wherein the n-mer comprises from about 4 to about 50 nucleotides.
7. The method of claim 1, wherein the mutation is a substitution mutation.
8. The method of claim 1, wherein the mutation is a deletion mutation.
9. The method of claim 1, wherein the mutation is an insertion mutation.
10. The method of claim 1, in which said target polynucleotide is selected from the group consisting of: a cystic fibrosis transmembrane conductance regulator gene, a p53 gene, a mitochondrial DNA, or an HIV gene.
11. The method of claim 1, wherein the arrays are arranged in parallel.

A2
S₁
S₂

12. (Amended) A method of determining whether two or more target polynucleotides are identical, comprising the steps of:
 - (a) providing at least two identical [or substantially identical] polynucleotide probe arrays, wherein each probe comprises a double stranded region and a

A2
cont

- single-stranded n-mer overhang region such that the overhangs in each array constitute a complete [or substantially complete] set of n-mers;
- (b) hybridizing first target polynucleotide to said overhangs of probe polynucleotides in one array to generate a first hybridization pattern;
- (c) hybridizing second target polynucleotide to said overhangs of probe polynucleotides in a second array to generate a second hybridization pattern; and
- (d) comparing the first and second hybridization patterns.

13. The method of claim 12, wherein in step b), the hybridized target polynucleotide is ligated to the probe.
14. The method of claim 12, wherein in step c), the hybridized reference polynucleotide is ligated to the probe.
15. The method of claim 12, wherein the overhangs have free 5'-ends.
16. The method of claim 12, wherein the overhangs have free 3'-ends.
17. The method of claim 12, wherein the n-mer comprises from about 4 to about 50 nucleotides.
18. The method of claim 12, wherein the arrays are arranged in parallel.

Please cancel Claims 19-25.

REMARKS

Claim numbers 1-25 are pending in the application. Claim numbers 1-25 are rejected under 35 U.S.C. §112. Claim numbers 1-25 are also rejected under 35 U.S.C. §103(a).

Discussion

Rejection of Claims 1-25 under 35 U.S.C. §112:

- a. Claims 1-25 are rejected as being indefinite in the recitations of "substantially identical" and "substantially complete." While applicant respectfully traverses